ÂÜÀòÂÒÂ×

Rachel Dusek has over 20 years of work experience in the field of translational medicine. From 1999 to 2006, they were a Graduate Student and Postdoctoral Fellow at Northwestern University - The Feinberg School of Medicine, where they developed expertise in epithelial biology and identified the desmosome protein desmoglein 1 as a novel caspase and metalloproteinase target. From 2006 to 2011, they were a Senior Scientist, Director of Target Validation, and Senior Director of Preclinical Development and San Jose R&D Site Head at Oxford BioTherapeutics, where they co-managed company-wide discovery and preclinical research for novel oncology and immuno-oncology therapeutics, provided strategic guidance on development candidates and pipeline prioritization, and oversaw scientific operations at the San Jose site. From 2018 to 2022, they were an Associate Director and Director of Translational Medicine at Clovis Oncology, where they operated as Translational Medicine lead for multiple Ph1b/Ph2 clinical trials and coordinated the testing of patient samples to analyze genomic/transcriptomic/proteomic biomarkers. Rachel is currently the Vice President of Translational Medicine at Nalo Therapeutics, Inc.

Rachel Dusek obtained their BA in Biology from Illinois Wesleyan University between 1993 and 1997. Rachel then went on to earn their PhD in Cancer Biology from Northwestern University between 1999 and 2005.